Science and Research
Clinical biomarkers research
Our researchers uncover new markers of eye disease using advanced imaging and functional tests. These markers are used to fast-track discovery of new treatments and transform eye care to prevent irreversible vision loss.
Why this research is important
One of the major barriers in the discovery of new treatments for conditions like age-related macular degeneration (AMD) and glaucoma is the need for large, lengthy and costly clinical trials.
These trials often require thousands of people over many years to assess each potentially promising therapy.
Our research aims to fast-track the discovery of sight-saving treatments by identifying new biomarkers that will help us better assess their effectiveness in a shorter timeframe.
These biomarkers also help us discover new pathways involved in causing these eye diseases, and this knowledge is used to guide the development of new therapies.
New clinical biomarkers are also used to diagnose eye diseases and their progression earlier, and to determine who is at the highest risk of vision loss.
They are crucial in our development of individualised approaches to eye care and prevention of irreversible sight loss.
Key research questions
- How can we speed up the discovery of new treatments to prevent the development, and/or worsening, of vision-threatening late AMD complications and glaucoma?
- How can we better predict who will develop vision loss amongst those with the early stages of AMD, and those with glaucoma under routine care?
- How can we accurately detect the earliest signs of glaucoma and its worsening?
- What are the underlying causes driving vision loss in AMD and glaucoma?
Associate Professor Peter van Wijngaarden
Associate Professor Peter van Wijngaarden is an ophthalmologist and medical scientist with research interests in diabetic retinopathy, Alzheimer’s disease and retinal imaging biomarker discovery. He has research experience in retinal vascular biology and central nervous system regeneration.